{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:10:28Z","timestamp":1781104228927,"version":"3.54.1"},"reference-count":115,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA266612"],"award-info":[{"award-number":["R01 CA266612"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and\/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among these are the anti-CD38 antibodies daratumumab and isatuximab, and the anti-Signaling lymphocytic activation molecule family member 7 antibody elotuzumab, all of which are used in their unconjugated formats. Single-chain variable fragments from antibodies also form a key element of the chimeric antigen receptors (CARs) in the B-cell maturation antigen (BCMA)-targeted CAR T-cell products idecabtagene vicleucel and ciltacabtagene autoleucel, which are approved in the advanced setting. Most recently, the bispecific anti-BCMA and T-cell-engaging antibody teclistamab has become available, again for patients with relapsed\/refractory disease. Another format into which antibodies can be converted to exert anti-tumor efficacy is as antibody\u2013drug conjugates (ADCs), and belantamab mafodotin, which also targets BCMA, represented the first such agent that gained a foothold in myeloma. Negative results from a recent Phase III study have prompted the initiation of a process for withdrawal of its marketing authorization. However, belantamab remains a drug with some promise, and many other ADCs targeting either BCMA or other plasma cell surface markers are in development and showing potential. This contribution will provide an overview of some of the current data supporting the possibility that ADCs will remain a part of our chemotherapeutic armamentarium against myeloma moving forward, and also highlight areas for future development.<\/jats:p>","DOI":"10.3390\/ph16040590","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T09:23:43Z","timestamp":1681464223000},"page":"590","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antibody\u2013Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?"],"prefix":"10.3390","volume":"16","author":[{"given":"Upasana","family":"Ray","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA"},{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX 77030-4009, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Improved survival in multiple myeloma during the 2005\u20132009 and 2010\u20132014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1111\/cas.15163","article-title":"Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine","volume":"112","author":"Shimazu","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-019-03858-w","article-title":"Treatment evolution and improved survival in multiple myeloma in Taiwan","volume":"99","author":"Tang","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: Results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-med-112017-091045","article-title":"New Drugs in Multiple Myeloma","volume":"70","author":"Kunacheewa","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current Treatment Strategies for Multiple Myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2848","article-title":"Sequencing of myeloma therapy: Finding the right path among many standards","volume":"39","author":"Rajkumar","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41416-020-01179-8","article-title":"Endocytosis: A pivotal pathway for regulating metastasis","volume":"124","author":"Khan","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fimmu.2019.00464","article-title":"The Human FcgammaRII (CD32) Family of Leukocyte FcR in Health and Disease","volume":"10","author":"Anania","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fcgamma Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates","volume":"39","author":"Aoyama","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jlb.54.5.504","article-title":"Soluble Fc gamma receptors","volume":"54","author":"Fridman","year":"1993","journal-title":"J. Leukoc. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_26","first-page":"35","article-title":"Clinical trials with blocked ricin immunotoxins","volume":"234","author":"Esseltine","year":"1998","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-2141.1998.00799.x","article-title":"Anti-B4-blocked ricin: A phase II trial of 7 day continuous infusion in patients with multiple myeloma","volume":"102","author":"Grossbard","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo","volume":"20","author":"Alavi","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience","volume":"11","author":"Vaxman","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.clml.2022.08.003","article-title":"Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed\/Refractory Multiple Myeloma","volume":"22","author":"Atieh","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study","volume":"200","author":"Shragai","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design","volume":"17","author":"Nooka","year":"2021","journal-title":"Future Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"gamma-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/JCO.2022.40.16_suppl.8019","article-title":"Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-5 study","volume":"40","author":"Lonial","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Popat, R., Nooka, A., Stockerl-Goldstein, K., Abonour, R., Ramaekers, R., Khot, A., Forbes, A., Cindy Lee, C., Augustson, B., and Spencer, A. (2020, January 5\u20138). DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib\/Dexamethasone (BorDex) in Relapsed\/Refractory Multiple Myeloma (RRMM). Proceedings of the 62nd ASH Annual Meeting and Exposition, San Diego, CA, USA. Abstract 1419.","DOI":"10.1182\/blood-2020-139332"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2022.40.16_suppl.8017","article-title":"Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis","volume":"40","author":"Quach","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2022.40.16_suppl.8018","article-title":"Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-4 Study","volume":"40","author":"Suvannasankha","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_51","unstructured":"Trudel, S., McCurdy, A., Fu, M., Sutherland, H.J., Louzada, M.L., Chu, M.P., White, D.J., Mian, H.S., Kotb, R., and Othman, I. (2022, January 10\u201313). Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed\/Refractory Multiple Myeloma. Proceedings of the 64th ASH Annual Meeting and Exposition, New Orleans, LA, USA. Abstract 3248."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Terpos, E., Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., and Syrigou, R. (2022, January 10\u201313). A Phase 1\/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Proceedings of the 64th ASH Annual Meeting and Exposition, New Orleans, LA, USA. Abstract 1920.","DOI":"10.1182\/blood-2022-162241"},{"key":"ref_53","unstructured":"Gonzalez-Calle, V., Otero, P.R., Rey-Bua, B., De La Rubia, J., De Arriba, F., Caba\u00f1as, V., Garcia, E.G., Ocio, E.M., Encinas, C., and Cabrera, A.S. (2022, January 10\u201313). Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial. Proceedings of the 64th ASH Annual Meeting and Exposition, New Orleans, LA, USA. Abstract 3241."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00277-022-04890-z","article-title":"Belantamab mafodotin in patients with relapsed\/refractory AL amyloidosis with myeloma","volume":"101","author":"Zhang","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41408-022-00717-2","article-title":"High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis","volume":"12","author":"Khwaja","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kastritis, E., Palladini, G., Dimopoulos, M.-A., Jaccard, A., Merlini, G., Theodorakakou, F., Fotiou, D., Minnema, M.C., Wechalekar, A.D., and Varghese, S. (2022, January 10\u201313). Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. Proceedings of the 64th ASH Annual Meeting and Exposition, New Orleans, LA, USA. Abstract 3244.","DOI":"10.1182\/blood-2022-169688"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov. Today Technol"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","article-title":"HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells","volume":"20","author":"Ko","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood-2018-99-118412","article-title":"HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to \u03b1-Amanitin, Is Active against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p","volume":"132","author":"Singh","year":"2018","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-141615","article-title":"The anti-B-cell maturation antigen (BCMA) antibody-\u03b1-amanitin conjugate HDP-101 induces immunogenic cell death and immunologic memory in models of multiple myeloma","volume":"136","author":"Singh","year":"2020","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kaufman, J.L., Orlowski, R.Z., Strassz, A., Pahl, A., Michaels, T., Last, A., Szaboki, H., Jentsch, G., Schoenborn-Kellenberger, O., and Raab, M.-S. (2022, January 10\u201313). Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study. Proceedings of the 64th ASH Annual Meeting and Exposition, New Orleans, LA, USA. Abstract 3219.","DOI":"10.1182\/blood-2022-168848"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression","volume":"27","author":"Xing","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kumar, S.K., Migkou, M., Bhutani, M., Spencer, A., Ailawadhi, S., Kalff, A., Walcott, F., Pore, N., Gibson, D., and Wang, F. (2020, January 5\u20138). Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed\/Refractory Multiple Myeloma. Proceedings of the 62nd ASH Annual Meeting and Exposition, San Diego, CA, USA. Abstract 179.","DOI":"10.1182\/blood-2020-136375"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A.C., and Gramignoli, R. (2019). CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies. Cells, 8.","DOI":"10.3390\/cells8121527"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"LB-227","DOI":"10.1158\/1538-7445.AM2020-LB-227","article-title":"Abstract LB-227: Preclinical development and characterization of STI-6129, an anti-CD38 antibody-drug conjugate, as a new therapeutic agent for multiple myeloma","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/1538-7445.AM2019-2384","article-title":"Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma","volume":"79","author":"Willert","year":"2019","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136928","article-title":"TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells","volume":"136","author":"Bruins","year":"2020","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"A475","DOI":"10.1136\/jitc-2021-SITC2021.447","article-title":"447 Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma","volume":"9","author":"Kumar","year":"2021","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.clml.2019.09.192","article-title":"TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFN\u03b1) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo","volume":"19","author":"Fatholahi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.HS9.0000843616.11738.cb","article-title":"S181: Modakafusp Alfa (TAK-573): Updated Clinical, Pharmacokinetic (PK), and Immunogenicity Results from a Phase 1\/2 Study in Patients (PTS) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"6","author":"Kaufman","year":"2022","journal-title":"HemaSphere"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/2643-3230.BCD-21-0205","article-title":"Perspectives on the Risk-Stratified Treatment of Multiple Myeloma","volume":"3","author":"Davies","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Reina, M., and Espel, E. (2017). Role of LFA-1 and ICAM-1 in Cancer. Cancers, 9.","DOI":"10.20944\/preprints201709.0146.v1"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.1158\/1078-0432.CCR-20-0400","article-title":"Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma","volume":"26","author":"Sherbenou","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1158\/1078-0432.CCR-14-3090","article-title":"A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"Hansson","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wichert, S., Juliusson, G., Johansson, A., Sonesson, E., Teige, I., Wickenberg, A.T., Frendeus, B., Korsgren, M., and Hansson, M. (2017). A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171205"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Paiva","year":"2016","journal-title":"Cytometry. Part B Clin. Cytom."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-04-0142","article-title":"In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2\u2032-deacetyl-N2\u2032-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells","volume":"64","author":"Tassone","year":"2004","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and\/or Refractory CD-56-positive Multiple Myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00011-016-0995-1","article-title":"The biological function and significance of CD74 in immune diseases","volume":"66","author":"Su","year":"2017","journal-title":"Inflamm. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"djw131","DOI":"10.1093\/jnci\/djw131","article-title":"Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response","volume":"108","author":"Zheng","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-04-0182","article-title":"CD74 is expressed by multiple myeloma and is a promising target for therapy","volume":"10","author":"Burton","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","article-title":"Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys","volume":"11","author":"Sapra","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.12565","article-title":"Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma","volume":"163","author":"Kaufman","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-139829","article-title":"Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma","volume":"136","author":"Shah","year":"2020","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1078-0432.CCR-19-1431","article-title":"First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7\/CS1 in Patients with Relapsed and Refractory Multiple Myeloma","volume":"26","author":"Vij","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/leu.2011.290","article-title":"Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells","volume":"26","author":"Lamorte","year":"2012","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-16-0232","article-title":"Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth","volume":"76","author":"Beauvais","year":"2016","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: A multicentre, phase 1\/2a study","volume":"8","author":"Kelly","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","article-title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer","volume":"39","author":"Kollmannsberger","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/1078-0432.CCR-14-2093","article-title":"Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)","volume":"21","author":"Uppal","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-16-0710","article-title":"Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-020-00378-z","article-title":"VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo","volume":"10","author":"Yu","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/58.5.1247","article-title":"Growth kinetics of plasma cell myeloma","volume":"58","author":"Drewinko","year":"1977","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V55.3.364.364","article-title":"Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma","volume":"55","author":"Durie","year":"1980","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/bloodadvances.2019001346","article-title":"CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma","volume":"4","author":"Ramkumar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lowther, D.E., Houseman, E.A., Han, G., Kleanthous, E., Knoblock, D., Zhou, X., Banerjee, S., Patel, S., and Figueroa, D. (2022, January 10\u201313). No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Proceedings of the 64th ASH Annual Meeting and Exposition, New Orleans, LA, USA. Abstract 248.","DOI":"10.1182\/blood-2022-157767"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Dietrich","year":"2021","journal-title":"Nat. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/590\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:15:58Z","timestamp":1760123758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":115,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040590"],"URL":"https:\/\/doi.org\/10.3390\/ph16040590","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]}}}